Polycystic Ovary Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) in a landmark shift based on global consensus.
The PCOS-to-PMOS shift follows a 14-year global collaborative effort led by Monash University and the AE-PCOS Society, involving 50 organizations and 22,000 survey respondents.
The new name, PMOS, published in The Lancet, aims to correct the medical inaccuracy of term cysts and understand the condition which affects more than 170 million women, through intersectionality of metabolic, hormonal and mental health impacts.
The rebranding of the name is also meant to educate people that PCOS is not just about ovarian cysts or reproductive systems, but a complex endocrine and metabolic condition that can impact the entire body.
Because in traditional terms, PCOS is just a hormonal-based issue, not the condition with a systemic endocrine disorder.
The new name avoids certain reproductive terms that carry cultural stigma in various parts of the world.
Professor Helena Teede, Director, Monash Centre for Health Research & Implementation and endocrinologist, Monash Health, Melbourne, Australia, who led the name change process, said, “What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated.”
“It was heart breaking to see the delayed diagnosis, limited awareness, and inadequate care afforded those affected by this neglected condition.”
Implementation timeline
According to the organization, a three-year education and awareness campaign is currently active. The name will be fully integrated into the 2028 International Guideline update.
Why does this shift matter for millions of women?
For millions of women in the world, this distinction matters because change in language and understanding can shape medical treatment, research priorities, self-understanding, public understanding and mental.
Because for years, people struggling with PMOS have faced many challenges related to delayed diagnosis, shame around symptoms, fertility assumptions, and mental health struggles that were not fully acknowledged.
Professor Teede added, “The agreed principles of the new name included patient benefit, scientific accuracy, ease of communication, avoidance of stigma, cultural appropriateness and accompanying implementation.”
Medical experts and advocates believe that the name change will reshape how we see the symptoms and treatment. The shift is expected to bring earlier diagnoses and more thorough treatment.
As per experts, PMOS will move beyond the narrow reproductive frame and promote accurate diagnosis, reduce cultural barriers and stigma, support holistic care, and expand research from hormonal to metabolic realm.
According to Melanie Cree, MD, PhD, a pediatric endocrinologist at the University of Colorado Anschutz, “What makes this effort especially powerful is that it sets the foundation for meaningful change, from medical education to clinical guidelines to public awareness, and ultimately, better outcomes for patient care.”
In a nutshell, PMOS is not just a name change; it is a historic shift towards recognizing it as real, multifaceted, systematic, deserving of comprehensive care and research
